路透10月8日 - 维亚特里斯(Viatris) VTRS.O 周四表示,已同意以16.5亿美元收购帕西拉生物科学公司(Pacira Biosciences) PCRX.O,将这家镇痛疗法制造商的产品纳入其产品组合,以期拓展其创新药物业务。
路透10月8日 - 维亚特里斯(Viatris) VTRS.O 周四表示,已同意以16.5亿美元收购帕西拉生物科学公司(Pacira Biosciences) PCRX.O,将这家镇痛疗法制造商的产品纳入其产品组合,以期拓展其创新药物业务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.